摘要
红细胞输注是治疗早产儿贫血的重要手段。但在以下3个方面还存在争议:(1)早产儿红细胞输注相关并发症;(2)早产儿红细胞输注指征;(3)针对早产儿红细胞制品的选择。近年来,随着研究的深入,上述问题取得了一些新进展,有些已应用于临床。这些理念及措施的实施使早产儿贫血得到必要、及时的治疗,降低了早产儿红细胞输注相关并发症的发生率,改善了患儿的预后。现就早产儿红细胞输注的相关研究进展进行综述。
Red blood cell transfusion is an important method to treat anemia of prematurity.However, there are 3 areas of controversy:(1) complications associated with red blood cell transfusion in preterm infants;(2) indications of red blood cell transfusion in preterm infants;(3)which kind of red blood cell products is more suitable for preterm infants.In recent years, with the deepening of research, these problems above have made some new progress and they have been applied to clinic.The implementation of these ideas and measures makes the premature infants with anemia get reasonable treatment, and reduces incidence of complications associated with red blood cell transfusion in preterm infants, and improves the prognosis of those sick preterm infants.Now, the new progress of red blood cell transfusion in preterm infants was reviewed.
作者
肖一涵
曾超美
Xiao Yihan;Zeng Chaomei(Department of Pediatrics,Peking University People′s Hospital,Beijing 100044,China)
出处
《中华实用儿科临床杂志》
CSCD
北大核心
2019年第6期468-472,共5页
Chinese Journal of Applied Clinical Pediatrics
关键词
婴儿
早产
红细胞输注
并发症
Infant, preterm
Red blood cell transfusion
Complication
